Control of cell proliferation by cell volume alterations in rat C6 glioma cells.
K+ and Cl- channels are involved in regulating the proliferation of a number of cell types. Two main hypotheses have been proposed to explain the mechanism by which these channels influence cell proliferation: regulation of membrane potential and regulation of cell volume. In order to test these hypotheses, we measured, under different experimental conditions, the volume, membrane potential and rate of proliferation of C6 glioma cells. Cells cultured in control medium for 1-4 days were compared with cells cultured for the same period of time in the presence of broad spectrum channel blockers: tetraethylammonium, 5-nitro-2-(3-phenylpropylamino) benzoic acid (NPPB) and Cs+, in hypertonic media (29% increased osmolarity with NaCl, KCl or sucrose), in hypotonic medium (23% decreased osmolarity with H2O) or in the presence of the specific channel blockers, i.e. mast cell degranulating peptide, charybdotoxin or chlorotoxin. In all of these conditions, we observed a close correspondence between the rate of proliferation and the mean cell volume. The proliferation decreased when volume increased. Moreover, whereas control cells were flattened, spindle-shaped, bipolar or multipolar, cells cultured in media supplemented with NPPB, KCl or CsCl were round with few processes. Of the agents tested, only KCl and Cs+ depolarized the cells. These results show that alterations of the rate of proliferation by K+ and Cl- channel blockers or anisotonia are closely related with changes in cell volume or form but are not correlated with changes in membrane potential.
Rouzaire-Dubois
B
B
Laboratoire de Neurobiologie Cellulaire et Moléculaire, CNRS UPR 9040, Gif-sur-Yvette, France.
Milandri
J B
JB
Bostel
S
S
Dubois
J M
JM
D000818:Animals; D002455:Cell Division; D048429:Cell Size; D002586:Cesium / Q000494:pharmacology; D018999:Charybdotoxin / Q000494:pharmacology; D018118:Chloride Channels / Q000037:antagonists & inhibitors / Q000502:physiology; D003470:Culture Media; D004533:Egtazic Acid / Q000494:pharmacology; D005910:Glioma / Q000473:pathology*; D007473:Ion Channels / Q000037:antagonists & inhibitors; D008564:Membrane Potentials / Q000502:physiology; D009579:Nitrobenzoates / Q000494:pharmacology; D009994:Osmolar Concentration; D010455:Peptides / Q000494:pharmacology; D026902:Potassium Channel Blockers; D015221:Potassium Channels / Q000502:physiology; D011189:Potassium Chloride / Q000008:administration & dosage; D051381:Rats; D012604:Scorpion Venoms / Q000494:pharmacology; D012965:Sodium Chloride / Q000008:administration & dosage; D013395:Sucrose / Q000008:administration & dosage; D019789:Tetraethylammonium / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D018118:Chloride Channels; D003470:Culture Media; D007473:Ion Channels; D009579:Nitrobenzoates; D010455:Peptides; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D012604:Scorpion Venoms; C091539:Chlorotoxin; D018999:Charybdotoxin; D002586:Cesium; C008331:mast cell degranulating peptide; C058176:5-nitro-2-(3-phenylpropylamino)benzoic acid; D012965:Sodium Chloride; D004533:Egtazic Acid; D013395:Sucrose; D019789:Tetraethylammonium; D011189:Potassium Chloride